The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Developing A Vaccine To Protect Against Hypervirulent Strains Of Group A Streptococcus
Funder
National Health and Medical Research Council
Funding Amount
$536,850.00
Summary
Epidemic invasive GAS disease is associated with the emergence of the globally disseminated M1T1 clone and is linked to the mutation in the CovR/S regulator. This mutation leads to over- expression of SpyCEP and inhibits recruitment of neutrophils to the site of infection. Inclusion of an immunogenic fragment of SpyCEP into our current vaccine would enhance its efficacy and lead to the development of a vaccine with a wider coverage and better protective efficacy against hypervirulent GAS strains
Characterising The Molecular Pathogenesis Of Newly Emergent Invasive Group A Streptococcus M4 Serotypes In Australia
Funder
National Health and Medical Research Council
Funding Amount
$523,756.00
Summary
Group A Streptococcus (GAS) is a human pathogen of global significance, responsible for life-threatening invasive infections such as flesh-eating disease (>650,000 cases per year), with a mortality rate of 25%. A recent outbreak of serotype M4 GAS caused severe invasive infections in Queensland Australia. The aim of this work is to determine how M4 GAS causes invasive disease. Understanding this mechanism will allow the development of new generation therapeutics, treatments and improved healt ....Group A Streptococcus (GAS) is a human pathogen of global significance, responsible for life-threatening invasive infections such as flesh-eating disease (>650,000 cases per year), with a mortality rate of 25%. A recent outbreak of serotype M4 GAS caused severe invasive infections in Queensland Australia. The aim of this work is to determine how M4 GAS causes invasive disease. Understanding this mechanism will allow the development of new generation therapeutics, treatments and improved health outcomes.Read moreRead less
Role Of The Host Fibrinolytic System In Invasive Group A Streptococcal Disease
Funder
National Health and Medical Research Council
Funding Amount
$531,444.00
Summary
The flesh-eating bacterium group A streptococcus (GAS) is estimated to cause 700 million cases of self-limiting disease, and 600,000 cases of serious invasive disease each year. Approximately 25% of invasive infections are fatal. We have shown that GAS are able to hijack the host fibrinolytoc system to cause severe invasive infections. We plan to further examine the details of how this contributes to GAS disease. This research may contribute to the future devlopment of new therapeutics.
Should Very Premature Babies Receive A Placental Transfusion At Birth? A Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$2,875,774.00
Summary
Premature babies under 30 weeks gestation are up to a hundred times more likely than full term babies to die or survive with major disability, often from brain damage due to poor blood flow after birth. This randomised study will find out if giving them more placental blood at birth, by means of a delay in clamping the umbilical cord, then milking it, reduces anemia, blood transfusions, brain damage, infection, death and disability. The results may benefit millions of premature babies worldwide.